Seeking Alpha

AstraZeneca (AZN +0.8%) ticks higher after presenting final overall survival analysis on...

AstraZeneca (AZN +0.8%) ticks higher after presenting final overall survival analysis on Faslodex, which showed a 4.1 month difference in median overall survival when using Faslodex Injection 500 mg compared with 250 mg. Faslodex is a treatment for metastatic breast cancer in postmenopausal women. The findings were presented today at the 35th CTRC-AACR San Antonio Breast Cancer Symposium.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|